top of page
Fund Manager Summary on Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)
In February 2026, Firetrail Investments commented that Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) is a hospital‑focused respiratory device growth business whose patient‑friendly nasal cannula products are driving recurring consumable revenue, recent double‑digit revenue growth and strong earnings expansion (citing ~12% revenue growth and ~28% earnings growth) and apparent market share gains. Across fund manager commentary there is a clear consensus that FPH’s structural tailwinds—global leadership in humidified respiratory and acute care, a high‑recurring consumables mix (~89% of sales), meaningful R&D investment (NZ$226.9m; ~11% of revenue) and several new product rollouts (Airvo 3, F&P 950, Nova Micro/Nova Nasal, Optiflow and anaesthesia applications)—support medium‑term growth and margin recovery, while managers weigh this against tangible near‑term risks: policy/tariff exposure because manufacturing is outside the US (cited by Oracle, Paradice and others leading to portfolio exits), seasonal swings in hospital demand, freight and cost pressures, and the inherently slow, multi‑year process of changing clinical practice that governs adoption; operational data underpinning the bullish case include FY25 revenue NZ$2.02b and NPAT NZ$377.2m, gross margin improvement to 62.9% and net cash ~NZ$201m, with management guidance upgraded to FY26 revenue NZ$2.17–2.27b and NPAT NZ$410–460m, so the primary actionable considerations for investors and managers are monitoring tariff and trade policy developments, tracking clinical adoption and guideline evidence generation, assessing cadence of new product rollouts and consumables attach rates, and watching margin progression toward management targets (c.65% gross, ~30% operating); upside catalysts flagged by some managers include faster clinical conversion and a stronger respiratory season in the US, while downside triggers remain tariff escalation, slower adoption or renewed cost/margin pressure.
Commentary From The Managers
There are 21 insights from 9 fund managers regarding their investment in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Firetrail Investments
2 Feb 2026
$33.55
Summary
- Firetrail Investments believes Fisher & Paykel Healthcare is a high-quality growth business in the physical healthcare space and continues to hold because it combines patient-preferred respiratory technology, durable consumable revenue, strong market-share leadership and an attractive valuation.
- Not consumer fridges — the business is focused on hospital respiratory care, not household appliances.
- Core product: high-flow nasal cannula / nasal oxygen systems that replace full-face masks, improving patient comfort and experience (can talk, eat, less dry throat).
- Clinical validation: post-COVID research shows the nasal cannula approach is non-inferior to traditional mask therapy for many respiratory conditions, supporting broader adoption.
- Customer benefits drive adoption: better patient tolerance and clinical parity help hospitals prefer the device, accelerating replacement of older approaches.
- Recurring revenue mix: ~90% of hospital revenue comes from consumables — a highly recurring, sticky revenue pool.
- Market position: roughly 90% market share in relevant hospital segments, with ongoing share gains.
- Recent performance: revenue grew ~12% in the past year and earnings grew ~28%.
- Valuation: trading on one of the lowest multiples in nearly a decade, enhancing the risk/reward in Firetrail’s view.
- Strategic thesis: combination of clinical acceptance, patient preference, recurring consumables, strong competitive position and an attractive valuation underpin conviction to hold.
Paradice Investment Management
31 Dec 2025
$32.65
Summary
- Paradice Investment Management believes Fisher & Paykel Healthcare Ltd. displayed strong operational performance but sold their investment because of concerns over potential tariff hikes from a Section 232 investigation by the Trump administration and the potential renegotiation of the current USMCA agreement in North America.
- Section 232 risk: Concern that a Section 232 investigation could lead to tariff increases affecting exports or supply chains tied to the US market.
- USMCA renegotiation risk: Potential changes to the USMCA could materially alter trade terms in North America and increase operating or market access uncertainty.
- Operational fundamentals: Outside of policy and trade risks, the company’s underlying operational performance remained strong.
- Decision framework: The team prioritized policy and regulatory risk over positive operational indicators when deciding to exit the position.
- Action taken: Position in Fisher & Paykel Healthcare was exited due to the elevated geopolitical and trade-policy uncertainty.
Ten Cap
30 Nov 2025
$32.85
Summary
- Ten Cap initiated a position in Fisher & Paykel Healthcare Corporation Ltd (FPH) due to its potential to capitalize on a stronger flu season in the United States.
- Data indicates that vaccination rates have declined in recent years, which may lead to increased demand for respiratory products.
- Ten Cap sees upside risk to current earnings forecasts as demand for these products is expected to rise.
Selector Funds Management
30 Nov 2025
$32.85
Summary
- Selector Funds Management acknowledges Fisher & Paykel Healthcare's strong HY26 results, with revenue growth of 14% (12% cc) to NZ$1.09b.
- This marks the first instance of the company surpassing NZ$1b in half-year revenue.
- All segments performed well, with hospital revenue growing 17% (15% cc) to NZ$692m.
- Homecare revenue increased by 10% (8% cc) to NZ$396m.
- Gross margins improved by 110 basis points (60 basis points cc) to 63%.
- Operating income (EBIT) rose 31% to NZ$286m, achieving a 26.3% margin.
- The company is targeting long-term gross profit and operating margins of 65% and 30%, respectively.
- CEO Lewis Gradon highlighted broad-based strength in the Hospital consumables portfolio and successful performance of new homecare products.
- Fisher & Paykel Healthcare has raised its FY26 guidance to revenue of NZ$2.17b-NZ$2.27b and NPAT of NZ$410m-NZ$460m.
- The company's market capitalisation stands at $19b.
Selector Funds Management
31 Aug 2025
$33.32
Summary
- Selector Funds Management continues to hold Fisher & Paykel Healthcare due to its strong positioning in the global healthcare market.
- Insights from the investor day highlighted the company’s innovative approach post-COVID, focusing on changing clinical practices.
- General Manager Australia and Group CEO emphasized that the company is not at any inflection points, with opportunities described as "longer than my arm."
- The company’s competitive advantage lies in its unique approach to clinical change, providing solutions that others do not.
- Fisher & Paykel has a robust R&D team with over 1,000 staff, indicating a strong pipeline of future therapies.
- The company fosters long-term relationships with hospital customers, moving away from a transactional sales model.
- Improving patient outcomes is central to their sustainable growth strategy, driving clinical practice changes over time.
- Recent discussions at the investor day showcased the successful adoption of therapies like the Optiflow Nasal High Flow system in emergency departments.
- The Anaesthesia Optiflow Thrive System, recognized as the “standard of care,” exemplifies the company’s commitment to innovation and improving patient safety.
- Management employs a granular approach to investment planning, reviewing each product and market annually to ensure sustainable growth.
- Fisher & Paykel's ambition to double the business every 5-6 years is supported by detailed planning and a clear understanding of market dynamics.
- The adoption rate of therapies in Australia serves as a positive indicator for growth potential in larger markets like the U.S.
ELM Responsible Investments
31 July 2025
$34.09
Summary
- Fisher & Paykel Healthcare (FPH) is recognized as a global leader in respiratory and acute care, positively impacting the lives of 20 million patients annually worldwide.
- In 2025, the company reported a 16% revenue increase to NZ$2.02 billion and a 43% rise in net profit after tax, totaling NZ$377.2 million.
- Growth was fueled by new product launches and enhanced manufacturing efficiency.
- The hospital segment revenue grew by 18%, while homecare revenue increased by 13%.
- Operating and gross margins saw significant improvements, with gross margin reaching 62.9%.
- Despite ongoing challenges from tariffs and seasonal swings in hospital demand, the company anticipates revenue growth of around 10% in the coming years.
- ELM Responsible Investments continues to hold due to the forecast of FY26 net profit between NZ$390-440 million.
Hyperion Asset Management
31 July 2025
$34.09
Summary
- Hyperion Asset Management attended Fisher & Paykel Healthcare Corporation Ltd.'s Investor Day at Royal Melbourne Hospital.
- The event featured presentations from specialists in various hospital departments, highlighting the evolution of clinical practices that drive organic growth for Fisher & Paykel’s products.
- Presentations emphasized the strong value proposition of Fisher & Paykel’s offerings for both physicians and patients.
- Despite the value, changing clinical practices is a slow process influenced by multiple factors such as clinical guidelines and key opinion leaders.
- Fisher & Paykel's products, particularly Optiflow, provide warm, humidified oxygen for patients with respiratory distress.
- Optiflow helps stabilize breathing, reduces the need for invasive ventilation, and assists in recovery post-extubation.
- The use of Optiflow leads to faster recovery, fewer complications, and allows hospitals to treat patients in less acute settings.
- This not only results in cost savings but also increases ICU capacity.
- Hyperion Asset Management continues to hold Fisher & Paykel due to its strong fundamentals and growth potential in the healthcare sector.
Selector Funds Management
30 June 2025
$33.63
Summary
- Fisher & Paykel Healthcare, founded in 1969, is a leading global medical device manufacturer in humidified respiratory care and obstructive sleep apnea (OSA).
- Employs 7,506 staff across 55 countries, including New Zealand, North America, and Europe.
- 89% of revenue comes from recurring items, consumables, and accessories, sold in over 120 countries.
- In this quarterly edition, Selector Funds Management provides a detailed review of the business.
- Financial Year 2025 saw record top line sales up 16% to NZ$2.02b, with net profit rising 43% to NZ$377m.
- Hospital sales rose 18% to NZ$1.28b, aided by new premium products like Airvo 3 and 950 devices.
- Homecare product group contributed NZ$740m, with consumables rising 14% to NZ$651m.
- New applications in consumables now represent 74% of Hospital Consumables.
- Economies of scale improved financial outcomes, with gross profits lifting to NZ$1.27b and margins improving from 61.1% to 62.9%.
- R&D costs rose 14% to NZ$226m, representing 11% of group revenues, highlighting its importance as a competitive differentiator.
- Net cash at year-end was NZ$201m, with dividends raised 2% to NZ$0.425.
- Management has guided for FY26 revenue between NZ$2.15b to NZ$2.25b and net profit after tax of NZ$390m to NZ$440m.
- Selector Funds Management continues to hold Fisher & Paykel Healthcare due to its strong market position and growth potential.
Oracle Advisory Group
30 June 2025
$33.63
Summary
- Oracle Advisory Group sold their investment in Fisher Paykel due to concerns over Trump’s tariffs affecting Mexico, China, and New Zealand.
- Fisher Paykel has all its manufacturing facilities outside of the US, making it especially vulnerable to these tariffs.
- In hindsight, the decision to sell was timely, as the stock experienced a significant decline following the announcement of tariff impacts.
ELM Responsible Investments
31 May 2025
$34.84
Summary
- Fisher & Paykel Healthcare (FPH) is a global leader in respiratory and acute care, improving outcomes for 20 million patients annually.
- For FY2025, FPH achieved a record revenue of NZ$2.02 billion, marking a 16% increase from the previous year.
- Net profit after tax rose by 43% to NZ$377.2 million, driven by strong demand in both Hospital and Homecare segments.
- The Hospital product group, which includes ventilation and surgical care products, accounted for 63% of operating revenue, growing 18% to NZ$1.28 billion.
- Growth in the Hospital segment was fueled by the adoption of new applications and the rollout of F&P Airvo™ 3 and F&P 950™ systems in the U.S.
- The Homecare segment, focusing on sleep apnea and respiratory support, accounted for 37% of revenue and rose 13% to NZ$739.9 million.
- Sales of new products like Nova Micro™ and Nova™ Nasal masks contributed to Homecare growth.
- FPH invested NZ$226.9 million in research and development, supporting ongoing innovation.
- With a strengthened product portfolio and continued global demand, FPH is positioned for sustained growth in FY2026.
- ELM Responsible Investments continues to hold because of FPH's strong performance and growth potential.
Oracle Advisory Group
31 Mar 2025
$30.25
Summary
- Oracle Advisory Group sold their investment in Fisher Paykel (FPH) due to concerns about Trump's tariffs on Mexico, China, and New Zealand.
- FPH is particularly vulnerable as all manufacturing facilities are located outside the US.
- The decision to sell was timely, as the stock fell significantly following FPH's announcement regarding tariff impacts.
ELM Responsible Investments
31 Mar 2025
$30.25
Summary
- Fisher & Paykel Healthcare (FPH) is a global leader in products for respiratory care, acute care, and obstructive sleep apnea (OSA).
- FPH significantly improves patient outcomes, treating 20 million patients annually.
- In November 2024, FPH reported record first-half results for the 2025 financial year, with operating revenue of NZD 951.2 million, an 18% increase year-on-year.
- Homecare operating revenue grew by 14% to NZD 359.4 million, alongside a 14% increase in constant currency revenue for OSA masks and accessories.
- Net profit after tax reached NZD 153.2 million, up 43% from the previous year.
- Despite a strong market position, there exists substantial growth opportunity due to low penetration of FPH products in hospitals.
- This underpenetration is attributed to entrenched clinical practices and the adoption time required for new technologies.
- To leverage growth opportunities, FPH is expanding its sales force, accelerating R&D projects, and launching new products.
- In the 2024 financial year, FPH invested NZD 198.2 million in R&D, representing 11% of its revenue.
- New product launches, such as the F&P Nova Micro™ nasal pillows mask for OSA, have received positive feedback and are set for broader distribution.
- FPH's market leadership, commitment to innovation, and focus on sustainability are key factors in ELM Responsible Investments' continued support.
Flagship Investments
31 Mar 2025
$30.25
Summary
- Flagship Investments sold their investment in Fisher & Paykel.
- The company is considered a quality business.
- It no longer met the fund's internal rate of return (IRR) threshold.
Centennial Asset Management
13 Jan 2025
$33.99
Summary
- Centennial Asset Management believes Zip has the potential to rally in the short term.
- Zip is well positioned to deliver further strong growth in revenues and profitability.
- The US buy now, pay later market remains relatively immature, allowing Zip’s US footprint to grow rapidly.
- New product launches are expected to contribute to the company’s transaction volumes and earnings growth in the coming year.
- Zip’s balance sheet strength and ongoing buyback are expected to support share price performance.
- Zip has surprised the market with better-than-expected earnings over the past year.
- The company has upgraded expectations post the most recent quarter, indicating potential for additional upside earnings risk.
Selector Funds Management
31 Dec 2024
$34.95
Summary
- Fisher & Paykel Healthcare is a prominent global medical device manufacturer specializing in humidified respiratory care and obstructive sleep apnea (OSA).
- Founded in 1969, the company employs 7,141 staff across 54 countries, including New Zealand, North America, and Europe.
- A significant portion of revenue (89%) is derived from recurring items, consumables, and accessories sold in over 120 countries.
- Fisher & Paykel Healthcare reported a solid half-year 2025 result, bolstered by efforts to change clinical practice and new product introductions.
- Gross profit margins increased by 141 basis points to 62% due to manufacturing efficiencies and company-wide improvement initiatives.
- Operating profit (EBIT) margin expanded by 394 basis points to 23%.
- Management remains confident in achieving a long-term gross profit margin target of 65% and a 30% EBIT margin within the next three years.
- In the Hospital segment, the company launched the next-generation respiratory humidification system (F&P 950) and the new Optiflow High Flow Therapy System (Airvo 3) in the U.S., leading to a 25% growth in hardware revenue.
- In Consumables, the new Optiflow Duet cannula mask is now available in most major markets, with Non-Invasive Ventilation (NIV) and Nasal High Flow (NHF) therapy remaining core growth drivers.
- Homecare continues to perform well, driven by the OSA mask portfolio, with new products like the Solo mask and Nova Micro mask being rolled out.
- The Solo mask features automatic fitting, while the Nova Micro mask is the smallest and lightest mask to date, with a U.S. launch expected in November.
- For FY25, the company reaffirms revenue guidance between NZ$1.9b and NZ$2.0b, with net profit after tax expected between NZ$320m and NZ$370m.
- Long-term aspirations include doubling revenue every five to six years, supported by R&D investments at 12% of revenue and a clear strategic vision.
- Short-term growth opportunities are seen in Optiflow for respiratory and anaesthesia patients, with medium-term prospects in home respiratory support and long-term goals in surgical technology.
- The total addressable market for Nasal High Flow is estimated at 150 million patients, with 6 million supported in FY24.
- Fisher & Paykel Healthcare has a market capitalization of $20.0b.
Selector Funds Management
30 Nov 2024
$34.63
Summary
- Fisher and Paykel Healthcare reported its HY25 result with revenue increasing 18% to NZ$951m, with 89% being recurring revenue.
- Operating profit (EBIT) rose 43% to NZ$218m.
- Growth was primarily driven by new product releases in the hospital and homecare divisions.
- Changes to clinical practice contributed to the positive results.
- Gross profit margins improved 140 basis points to 61.9%.
- Management anticipates returning to its long-term target of 65% gross profit margins over the next three years.
- Fisher & Paykel Healthcare has a market capitalisation of $19.8b.
Oracle Advisory Group
30 June 2024
$27.42
Summary
- Fisher & Paykel Healthcare is considered one of the best companies on the ASX.
- 89% of total revenues come from consumables, illustrating a perfected ‘Razor and Blades’ business model.
- Consumables are frequently changed in hospital settings, particularly in ICUs and for Nasal High Flow therapy.
- Fisher's NHF therapy is progressively replacing older therapies requiring manual oxygen flow adjustments.
- The company also has a robust home care division for Sleep Apnea patients.
- Fisher’s CPAP device is a strong competitor, ranking No. 3 after ResMed and Philips.
- The recent stock price increase was fueled by strong FY24 results.
- Revenues grew by 8% in constant currency compared to the previous year, with operating profit rising by 10%.
- Oracle Advisory Group continues to hold its position due to these promising fundamentals.
ELM Responsible Investments
30 June 2024
$27.42
Summary
- Fisher and Paykel Healthcare is a NZ-based medical device company specializing in respiratory care devices and systems.
- ELM Responsible Investments has been a long-term investor in FPH, currently holding it as their fourth largest position.
- Recent performance has been strong, but a review of the last four years highlights the impact of the COVID-19 pandemic on FPH's valuation.
- During the pandemic, FPH experienced exponential revenue growth, with market capitalization more than doubling from approx. US$6bn to US$13bn.
- After a sharp decline in 2022, FPH's market cap has gradually recovered to US$10bn.
- The latest annual report showed a 10% YoY increase in operating revenue, driven by an 18% growth in the Homecare product group.
- FPH committed 11% of operating revenue to R&D, reinforcing their position as a leading innovator in the industry.
- ELM Responsible Investments continues to hold because they are seeing the benefits of their long-term strategy and strong returns contributing to the fund's outperformance.
- Looking forward, FPH is positioned well as a market leader in respiratory devices, with growth expected due to an aging global population.
- The UN estimates that the global population aged over 65 will increase from 10% in 2022 to 16% in 2050, leading to higher healthcare needs that FPH can address.
Selector Funds Management
30 June 2024
$27.42
Summary
- Fisher & Paykel Healthcare, founded in 1969, is a leading global medical device manufacturer in humidified respiratory care and obstructive sleep apnea (OSA).
- The company employs 7,100 staff across 54 countries, including New Zealand, North America, and Europe.
- A large portfolio of revenue (89%) comes from recurring items, consumables, and accessories, sold in more than 120 countries.
- Fisher & Paykel Healthcare posted a solid financial year 2024 result, driven by double-digit revenue growth in its hospital new application consumables (+15%) and homecare OSA face masks (+18%).
- The business continues to shift towards greater recurring revenue, with consumable revenue representing 90% and 88% of total hospital and homecare revenue respectively.
- Underlying gross margins increased 172 basis points to 61.1%, benefiting from improved freight rates and manufacturing efficiencies.
- Fisher & Paykel is confident in its ability to return to its longer-term gross margin and operating margin (EBIT) target of 65% and 30% respectively.
- In the Hospital division, consumable growth was driven by its Non-Invasive Ventilation (NIV) and Nasal High Flow (NHF) therapy offerings.
- The company received regulatory clearance in the U.S. for its new generation respiratory humidification system (F&P 950) and a new NHF canular mask (Optiflow Duet).
- During FY24, NHF was administered to 6 million patients out of an estimated total addressable market of 150 million patients.
- The Homecare segment continues to perform strongly, led by the company’s OSA mask portfolio.
- Fisher & Paykel launched its new Solo mask across New Zealand, Australia, and Canada, with U.S. approval expected in the first half of FY25.
- The company announced its smallest and lightest mask to date (Nova Micro Nasal Pillows mask), live in New Zealand and launching soon in Canada, Australia, and Europe.
- For full year 2025, Fisher & Paykel expects operating revenue between NZ$1.9b and NZ$2.0b, an increase of 9%-15%.
- Net profit after tax is projected at NZ$310m to NZ$360m.
- Longer term, the company aspires to double constant currency revenue every 5-6 years through ongoing product innovation.
- Fisher & Paykel Healthcare has a market capitalisation of $16b.
ELM Responsible Investments
31 May 2024
$27.20
Summary
- Fisher & Paykel Healthcare (FPH) reported FY24 results with a 10% increase in revenue, reaching $NZ1.74 billion, driven by strong demand for hospital consumables.
- Obstructive sleep apnea (OSA) masks segment showed robust growth, contributing significantly to overall performance.
- Reported net profit after tax was $NZ132.6 million, impacted by one-off items totaling $NZ137 million, including a product recall.
- Excluding one-off items, underlying net profit after tax increased by 6% to $264.4 million.
- Hospital operating revenue grew by 6% to $NZ1.1 billion, with notable increases in new applications consumables (15%) and homecare operating revenue (18%).
- FPH invested 11% of revenue ($NZ198.2 million) in R&D, which is anticipated to decrease to around $NZ150 million in 2024-25.
- Looking ahead, FPH projects revenue between $1.9 billion and $2.0 billion and net profit after tax between $310 million and $360 million.
- CEO Lewis Gradon emphasized a return to a growth trajectory, stating the company has an impressive product portfolio and strong customer relationships.
- In 2024, FPH made progress towards its long-term gross margin target of 65%, with an underlying gross margin of 61.1%.
- Before the pandemic, FPH consistently delivered double-digit growth, and while revenue fluctuated post-pandemic, the company is expected to return to strong growth trends.
- ELM Responsible Investments continues to hold FPH due to the potential for significant shareholder gains as the company transitions back to pre-pandemic growth.
ELM Responsible Investments
31 Jan 2024
$22.14
Summary
- ELM Responsible Investments notes that Fisher & Paykel Healthcare has revised its fiscal year 2024 revenue forecast upward to $1.73 billion.
- The company also increased its net profit after tax estimate to a range of $260-265 million.
- Fisher & Paykel Healthcare experienced significant growth in its Hospital segment during the pandemic, driven by demand for ventilators, masks, and respiratory care products.
- Despite a decline in sales as global COVID-19 hospitalizations decreased, the company has a strong foundation due to its life-saving devices and consumables used for various diseases.
- ELM Responsible Investments continues to hold because of the company's long-term growth potential and ongoing need for its products beyond the pandemic.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
Fund managers including Centennial Asset Management, Oracle Advisory Group, ELM Responsible Investments, Selector Funds Management, Flagship Investments, Hyperion Asset Management, Ten Cap, Paradice Investment Management and Firetrail Investments have invested in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH).
Why do fund managers invest in Fisher & Paykel Healthcare Corporatn Ltd?
Fund managers invest in Fisher & Paykel Healthcare Corporation Ltd due to its strong market position in respiratory and acute care, evidenced by consistent revenue growth and expanding profit margins. With 89% of its sales from recurring consumables, it benefits from a stable revenue stream. Recent reports highlight a significant increase in demand, driven by product innovations and favorable market conditions, particularly in the U.S. Additionally, effective risk management and robust financial metrics support a favorable risk/reward profile.
What happened to Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
Fisher & Paykel Healthcare is attracting investment due to its strong financial performance, marked by a 14% revenue growth to NZ$1.09 billion in HY26, driven by robust demand in both hospital and homecare segments. The company is well-positioned to benefit from an anticipated increase in respiratory product demand in the U.S., as a decline in vaccination rates raises potential earnings forecasts. Additionally, ongoing improvements in operational efficiency led to higher margins, and the upward revision of FY26 revenue and NPAT guidance reflects confidence in sustained growth.
What is the short interest in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
The short interest in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) is 0.08% which makes it the 424th most shorted stock on the ASX. Of the 587.3M shares that Fisher & Paykel Healthcare Corporatn Ltd has on issue, 485.1K have been sold short.
What does Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) do?
Fisher & Paykel Healthcare Corp. Ltd. engages in the design, manufacture, and marketing of products and systems for use in acute and chronic respiratory care, surgery, and treatment of obstructive sleep apnea. It operates through the following geographical segments: North America, Europe, Asia Pacific, and Other. The Other segment includes New Zealand, Latin America, Africa, and the Middle East. The company was founded in 1969 and is headquartered in Auckland, New Zealand.
faqs
q1
q2
q3
q4
q5
bottom of page